Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.

Cancer research - 15 Aug 2001

Keshelava N, Zuo J J, Chen P, Waidyaratne S N, Luna M C, Gomer C J, Triche T J, Reynolds C P

Abstract excerpt

Neuroblastomas can acquire a sustained high-level drug resistance during chemotherapy and especially myeloablative chemoradiotherapy. p53 mutations are rare in primary neuroblastomas, but a loss of p53 function could play a role in multidrug resistance. We determined p53 function by measuring induction of p21 and/or MDM2 proteins in response to melphalan (L-PAM) in seven L-PAM-sensitive and 11 L-PAM-resistant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cyclins

Share to Drug Resistance, Multiple

Share to Etoposide

Share to Melphalan

Share to Oncogene Proteins, Viral

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 11507071

Genes

PAM
MDM2
CAT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.PMID 11507071Read ↗

p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma.Semantic proximity Read ↗

p53 determines multidrug sensitivity of childhood neuroblastoma.Semantic proximity Read ↗

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.Semantic proximity Read ↗

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.Semantic proximity Read ↗

Small-Molecule MDM2 Antagonists as a New Therapy Concept for NeuroblastomaSemantic proximity Read ↗

Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.Semantic proximity Read ↗

Tools development for the investigation of p53 in neuroblastomaSemantic proximity Read ↗

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.Semantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

A p53 Drug Response Signature Identifies Prognostic Genes in High-Risk NeuroblastomaSemantic proximity Read ↗

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read ↗

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.